clinical trial · NCT07209111
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 150
Neoplasm MalignantCalderasibCetuximab
brief summary
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
started
Dec 4, 2025
primary completion
Apr 9, 2032
completion
Apr 9, 2032
last updated
Jun 12, 2026
official title
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol